Aravive Investor Presentation Deck

Initial Anti-Tumor Activity from Phase 1b PDAC Trial: 15 mg/kg Batiraxcept + Gemcitabine+ nab-Paclitaxel Best Response Confirmed Partial Response Stable Disease Progressive Disease Not Evaluable Not Applicable (died before any post-baseline scans) All P1b Patients (N = 21) 6 (29%) 5 (24%) 5 (24%) 3 (14%) 2 (10%) ¹ Confirmed Response rate in P3 study of gemcitabine + nab-paclitaxel was 23% (N Engl J Med 369;18 October 31, 2013) Data cutoff August 8, 2022 31

View entire presentation